503A vs 503B GLP-1 Compounding in 2026: Legal Framework, Regulators & Trimi's Pharmacy Partners
Patient-specific 503A prescriptions vs bulk 503B outsourcing — how compounded semaglutide and tirzepatide are made, who regulates each pathway, and what to verify before ordering.
When you order compounded semaglutide or tirzepatide through a telehealth provider, the medication is dispensed by a 503A community sterile compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA). The other compounding pathway — 503B outsourcing facilities — serves a different patient route entirely. Understanding the distinction matters because it determines who's regulating your pharmacy, what quality standards apply, and how to verify a provider's legitimacy.
At a glance: 503A vs 503B
| 503A (Community Sterile Compounding) | 503B (Outsourcing Facility) | |
|---|---|---|
| Patient pathway | Per individual prescription, named patient | Bulk batches, no patient-specific Rx required for compounding |
| Primary regulator | State Board of Pharmacy | FDA (registered + inspected) |
| Quality standard | USP <797> sterile compounding | Current Good Manufacturing Practice (cGMP) |
| Sells to | Direct-to-patient via prescription | Clinics, hospitals, healthcare providers |
| Typical GLP-1 use case | Telehealth direct-to-patient (Trimi, Mochi, Henry Meds) | In-office clinic administration |
503A: Community Sterile Compounding (Trimi's model)
A 503A pharmacy operates under FDCA Section 503A. The defining requirement: each compounded preparation must be dispensed per an individual prescription naming a specific patient. The pharmacy receives the prescription, compounds the medication, and ships it to that named patient. This is the standard pathway for compounded GLP-1 medications dispensed via telehealth, including all of Trimi's compounded semaglutide and tirzepatide fulfillment.
Regulatory oversight: state boards of pharmacy. Each state licenses 503A pharmacies operating within its borders and issues non-resident pharmacy permits to out-of-state pharmacies that wish to ship in. Texas State Board of Pharmacy, where Trimi's primary partner VialsRx (license #35264) is licensed, is one of the larger and more rigorously-inspected boards. Trimi's secondary partner GreenwichRx operates under similar state-board oversight.
Standard of practice: USP <797> "Pharmaceutical Compounding — Sterile Preparations" sets the minimum quality requirements — clean-room environmental classification (ISO Class 5/7), sterility testing, beyond-use dating, personnel training. State boards inspect for compliance.
503B: Outsourcing Facilities
503B outsourcing facilities, created by the Drug Quality and Security Act (DQSA) of 2013, are a federally-registered category that prepares compounded medications in BULK without requiring patient-specific prescriptions at the time of compounding. They sell to healthcare providers — hospitals, clinics, physician offices — that administer the medication to their patients on-site.
Regulatory oversight: FDA directly. 503B facilities must register annually with FDA, comply with cGMP (the same standard FDA-approved drug manufacturers follow), and undergo FDA inspections. The FDA maintains a public registry of 503B outsourcing facilities at fda.gov.
The trade-off: 503B's batch-compounding efficiency comes with much higher fixed costs (cGMP infrastructure, annual FDA registration, batch testing). 503B-compounded GLP-1s typically reach patients via in-office injection visits priced significantly higher than 503A direct-to-patient telehealth.
Which applies to your compounded GLP-1?
If you're getting compounded semaglutide or tirzepatide shipped to your home via a telehealth provider, you're receiving a 503A patient-specific compounded preparation. The prescription was issued by a licensed clinician naming you specifically, and the 503A pharmacy compounded that specific prescription. This is the pathway Trimi uses for 100% of direct-to-patient fulfillment.
If you're going to a clinic and receiving an in-office injection of compounded GLP-1, the medication likely came from a 503B outsourcing facility (or, in some cases, an in-clinic 503A preparation if the clinic operates its own compounding pharmacy).
How to verify a 503A pharmacy
For any 503A pharmacy dispensing compounded GLP-1 medications direct-to-patient, you can verify:
- State-board license status — search the pharmacy's licensing state's public database (e.g., pharmacy.texas.gov/dbsearch for VialsRx)
- Sterile-compounding designation — license should specify "Community Sterile Compounding"
- Sterile-risk level — Med or High (semaglutide/tirzepatide injections are Med-risk under USP <797>)
- Disciplinary history — state-board records will show any orders, fines, or warnings
- Pharmacist-in-charge (PIC) name — required to be a licensed pharmacist; verifiable via state board
- Non-resident pharmacy permits in patient's state — required to legally ship into the patient's state
Trimi's verifiable 503A partners
- VialsRx (primary, ~86% of fulfillment volume): Texas State Board pharmacy license #35264. Class: Community Sterile Compounding. Sterile-Risk Level Med. No prior disciplinary orders. PIC: F.B. Bucky Payne. Verify at pharmacy.texas.gov/dbsearch
- GreenwichRx (secondary, ~13%): 503A community sterile compounding; state board lookups available for verification.
Start with verifiable 503A compounding
Trimi's 503A partners are publicly licensed and verifiable. $99/mo semaglutide, $125/mo tirzepatide on annual plan.
Start your visitFAQs about 503A vs 503B compounding
What's the difference between a 503A and 503B pharmacy?
A 503A is a traditional community sterile compounding pharmacy that prepares medications PER INDIVIDUAL PRESCRIPTION for a specific patient. A 503B is an FDA-registered outsourcing facility that compounds in bulk for office-use distribution without patient-specific prescriptions. Both are authorized under the Drug Quality and Security Act (DQSA, 2013); they're regulated by different agencies and serve different patient pathways. For compounded GLP-1 medications dispensed direct-to-patient (semaglutide, tirzepatide), 503A is the standard.
Which compounding pathway is legal for compounded semaglutide and tirzepatide?
503A is the legal pathway for compounded GLP-1 medications dispensed direct-to-patient via telehealth. The pharmacy must receive an individual prescription naming the patient, then compound that specific prescription. 503B outsourcing facilities prepare bulk compounded medications for clinics and hospitals that administer in-office — not for direct-to-patient telehealth dispensing. After the FDA delisted tirzepatide (Oct 2024) and semaglutide (Feb 2025) from drug shortage, the patient-specific-prescription pathway under Section 503A remains active.
Is one safer than the other?
Neither is inherently safer — both are regulated, but differently. 503A pharmacies are overseen by state boards of pharmacy and must follow USP <797> sterile-compounding standards. 503B outsourcing facilities are FDA-registered and must comply with current Good Manufacturing Practice (cGMP) — more rigorous batch-testing requirements than 503A. For an individual patient receiving compounded GLP-1 via telehealth, the relevant safety question is whether the 503A pharmacy is in good standing with its state board (no disciplinary orders, current sterile-compounding certification) and operating per USP <797>.
Who regulates 503A pharmacies?
503A pharmacies are regulated primarily by state boards of pharmacy (e.g., Texas State Board of Pharmacy, California State Board of Pharmacy, New York Board of Pharmacy). FDA has authority over 503A facilities for some federal compliance areas (e.g., bulk-substance lists, USP standards), but the day-to-day enforcement, licensing, and inspection happens at the state level. For verifiable transparency, Trimi's primary pharmacy partner VialsRx holds Texas State Board pharmacy license #35264 (Class: Community Sterile Compounding, Sterile-Risk Level Med, no prior disciplinary orders, PIC: F.B. Bucky Payne); license status is publicly searchable at pharmacy.texas.gov/dbsearch.
Who regulates 503B outsourcing facilities?
503B outsourcing facilities are directly regulated by the FDA. They must register with the FDA, comply with cGMP, submit to FDA inspections, and report adverse events. The FDA maintains a public list of registered 503B outsourcing facilities at FDA.gov. State boards of pharmacy retain some authority over 503B facilities located within their states, but the primary regulator is the FDA.
Can I get compounded GLP-1 from a 503B facility?
Typically not directly. 503B facilities sell to clinics, hospitals, and other healthcare providers for office-use administration — not direct-to-patient. If a clinic in your area administers compounded GLP-1 injections in-office and sources from a 503B, you'd receive the medication during a clinic visit. The direct-to-patient telehealth model (Trimi, Mochi, Henry Meds, etc.) uses 503A pharmacies because individual patient prescriptions are required.
Why do prices differ between 503A and 503B compounded GLP-1?
503A pharmacies have lower per-dose preparation costs because they're not maintaining bulk-batch cGMP infrastructure, but they pay for sterile-compounding equipment and quality-assurance staff per state-board requirements. 503B facilities have higher fixed costs (cGMP compliance, FDA inspections, batch testing) spread across larger volumes. End-patient prices reflect total program economics: Trimi delivers compounded semaglutide at $99/mo (annual) via 503A pharmacy + telehealth efficiency vs $400-$700+/mo at in-office clinics sourcing from 503B suppliers.
Which pharmacies does Trimi use?
Trimi works with two 503A community sterile compounding pharmacies: VialsRx (Texas State Board pharmacy license #35264 — primary partner, ~86% of Trimi fulfillment volume) and GreenwichRx (secondary). Both are licensed for sterile compounding, both hold non-resident pharmacy permits to ship into all 50 states + DC. Trimi does not use 503B outsourcing facilities because the direct-to-patient telehealth model is built around the 503A patient-specific-prescription pathway.
Is the FDA shortage list relevant to 503A compounding?
Historically, when an FDA-approved drug was on the FDA shortage list, 503A pharmacies could compound copies of that exact drug under FDCA §503A(b)(1)(D). Tirzepatide was on the shortage list Dec 2022–Oct 2024; semaglutide Mar 2022–Feb 2025. After delisting, the FDA initially provided enforcement-discretion grace periods. As of May 2026, the 503A patient-specific-prescription pathway remains legal — clinicians can prescribe compounded semaglutide/tirzepatide when there's a documented clinical reason the FDA-approved finished product is not appropriate for the individual patient (dose, formulation, allergies, cost-of-access, etc.).
Related reading
The cornerstone comparison of all compliant compounded GLP-1 providers.
What to verify before starting compounded GLP-1.
Legal pathways for compounded GLP-1 after FDA shortage delisting.
Current FDA shortage list + 503A compounding implications.
Disclaimer: This article describes regulatory frameworks for compounded medications and is informational only — not legal or medical advice. Compounded semaglutide and tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies under FDCA Section 503A. Compounded medications are not FDA-approved as finished drugs; the active ingredients (semaglutide, tirzepatide) are FDA-approved as the basis for commercial brand products (Wegovy, Ozempic, Mounjaro, Zepbound). Always consult a licensed clinician about whether compounded GLP-1 medications are appropriate for your situation. **The FDA does not review or approve any compounded medications for safety or effectiveness.